India’s cancer burden hit 15.70 lakh cases in 2025. But with returns diverging and valuations stretching, which ...

The first Phase 3 data for a cancer vaccine has raised questions about whether the potential new treatment is needed.

On October 23 (local time), at the 2026 European Society for Medical Oncology (ESMO) Congress held in Madrid, Spain, TQB2102, a new-generation HER2 bispecific antibody-drug conjugate (ADC) ...

Swiss big pharma Roche has agreed to license ZW209, an experimental cancer immunotherapy from Vancouver-based Zymeworks, for ...

A multi-stage virtual screening campaign against the c-Myc/Max dimerization interface has identified two small molecules that ...

Tempus AI delivers robust 22% YoY revenue growth, forecasting $1.6bn in 2026 and demonstrating strong commercial traction.

Apothecary Pharma LLC is a compounding pharmacy in North Carolina. Compounded GLP-1s are not FDA-approved or name-brand.

Six-year NATALEE analysis showed ~20% reduction in risk of death compared to ET alone 1; Benefit increased over time in invasive disease-free survival and across key secondary end ...

Expanding on the unprecedented final results previously reported from the Phase 3 RASolute 302 trial, the exploratory ...

Zoci plus atezolizumab had an estimated 81.9% six-month rate without progression or death; Zai Lab expects to start a global ...

SOUTH SAN FRANCISCO, Calif., Oct. 23, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced updated clinical results that show promising anti-tumor activity and preliminary ...

Months before Vancouver-based Zymeworks agreed to license its experimental cancer treatment to Roche, the biotechnology company had already identified two Roche-linked drugs among its potential ...